Table 3.
Effects of apabetalone versus placebo on primary and secondary outcomes across CKD
| Variable | eGFR <60 ml/min per 1.73 m2 | eGFR ≥60 ml/min per 1.73 m2 | Interaction P Value a | ||||
|---|---|---|---|---|---|---|---|
| Placebo Event/n (%) | Apabetalone Event/n (%) | Adjusted HR (95% CI) | Placebo Event/n (%) | Apabetalone Event/n (%) | Adjusted HR (95% CI) | ||
| Primary outcome | |||||||
| MACE | 35/164 (21) | 13/124 (11) | 0.50 (0.26 to 0.96) | 114/1041 (11) | 112/1084 (10) | 0.96 (0.74 to 1.24) | 0.03 |
| Composite events | |||||||
| MACE and CHF | 41/164 (25) | 16/124 (13) | 0.48 (0.26 to 0.88) | 132/1041 (13) | 123/1084 (11) | 0.91 (0.71 to 1.17) | 0.03 |
| Components | |||||||
| CV death | 17/164 (10) | 6/124 (5) | 0.47 (0.18 to 1.24) | 38/1041 (4) | 39/1084 (4) | 1.02 (0.98 to 1.60) | 0.12 |
| Nonfatal MI | 20/164 (12) | 9/124 (7) | 0.59 (0.26 to 1.33) | 74/1041 (7) | 68/1084 (6) | 0.89 (0.64 to 1.24) | 0.26 |
| Nonfatal stroke | 6/164 (4) | 2/124 (2) | 0.57 (0.11 to 2.97) | 11/1041 (1) | 15/1084 (1) | 1.36 (0.62 to 2.96) | 0.20 |
| CHF hospitalization | 14/164 (9) | 3/124 (2) | 0.25 (0.07 to 0.92) | 34/1041 (3) | 26/1084 (2) | 0.76 (0.46 to 1.27) | 0.12 |
Shown are events and total subjects counts, percentage rates, HRs, and 95% CIs for indicated composite and component end points. All analyses are stratified for statin and country and adjusted for age and sex. See also Supplemental Table 1 for minimally adjusted HRs. HR, hazard ratio; 95% CI, 95% confidence interval; MACE, major adverse cardiovascular events; CHF, congestive heart failure; CV, cardiovascular; MI, myocardial infarction.
a
Interaction P values indicate differences by CKD status in the effect of apabetalone on event rates.